MoonLake ImmunotherapeuticsMLTX
MLTX
About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Employees: 100
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
55% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 31
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
32% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $8.56M
9% more capital invested
Capital invested by funds: $3.14B [Q3] → $3.43B (+$294M) [Q4]
6% more funds holding
Funds holding: 109 [Q3] → 115 (+6) [Q4]
1.55% more ownership
Funds ownership: 99.02% [Q3] → 100.57% (+1.55%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$66
65%
upside
Avg. target
$77
91%
upside
High target
$100
150%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Brian Abrahams 5% 1-year accuracy 3 / 66 met price target | 68%upside $67 | Outperform Initiated | 18 Mar 2025 |
Goldman Sachs Richard Law 50% 1-year accuracy 4 / 8 met price target | 83%upside $73 | Buy Maintained | 27 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 29% 1-year accuracy 96 / 335 met price target | 150%upside $100 | Buy Reiterated | 27 Feb 2025 |
Needham Serge Belanger 37% 1-year accuracy 45 / 123 met price target | 65%upside $66 | Buy Maintained | 27 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
MoonLake Immunotherapeutics: A Buy At Dips
MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed results from the ARGO study, sonelokimab demonstrated superior efficacy against Humira and Secukinumab, indicating strong potential for future success. Institutional sell-offs in late 2023 caused a drastic stock decline, but MLTX remains financially stable with a cash runway extending into 2027.
Neutral
GlobeNewsWire
2 weeks ago
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Neutral
GlobeNewsWire
1 month ago
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Positive
Seeking Alpha
3 months ago
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies using sonelokimab to target moderate-to-severe Hidradenitis Suppurativa patients in mid-2025. The unique nanobody structure of sonelokimab, binding to three IL-17 dimers, positions it as a potential best-in-class IL-17 inhibitor. Positive data from VELA-1, VELA-2, and VELA-TEEN studies could lead to a single BLA filing for sonelokimab, enhancing shareholder value.
Neutral
GlobeNewsWire
3 months ago
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA) MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpA Phase 2 and Phase 3 data read-outs across all target indications expected in 2025 (adult HS, and PPP) and 2026 (adolescent HS, PsA and axSpA) Data from the Phase 3 VELA-TEEN trial may be combined with the Phase 3 VELA program in adults with moderate-to-severe HS to support the first Biologics License Application (BLA) for the Nanobody® sonelokimab Zug, Switzerland, January 8, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that patients have been screened in three new trials across three new indications to evaluate sonelokimab, an investigational Nanobody® designed to treat inflammatory disease. The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA), in addition to adult patients with HS and active psoriatic arthritis (PsA).
Neutral
GlobeNewsWire
7 months ago
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET The event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). In addition, MoonLake will provide pipeline updates and details on additional catalysts for the 2024-2026 period, including for trials in new indications such as the Phase 2 trials of SLK in palmo-plantar pustulosis (PPP).
Positive
Seeking Alpha
9 months ago
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026.
Neutral
GlobeNewsWire
11 months ago
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
Positive
Seeking Alpha
11 months ago
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, MoonLake's nanobody potentially offers better tissue penetration. Financially, MoonLake is secure with a cash runway for nearly seven years, preparing for Phase 3 trials without immediate funding needs.
Neutral
GlobeNewsWire
11 months ago
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody ® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025 Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA) including unprecedented multi-domain responses across joints, skin and other domains, supporting potential best-in-class profile of sonelokimab Announced the imminent commencement of four additional clinical trials of sonelokimab across dermatology, and rheumatology, including innovative trials in palmo-plantar pustulosis (PPP), juvenile HS and seronegative spondyloarthritis Ended the first quarter with $547.1 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026 ZUG, Switzerland, May 7, 2024 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2024. Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
Charts implemented using Lightweight Charts™